سعر هيمليبرا 105مجم/0.7 مل فيال تحت الجلد 2024

Emicizumab 105 mg/0.7 ml single-dose vial for subcutaneous injection (Hemlibra, Roche), a bispecific factor IXa- and factor X-directed antibody for routine prophylaxis of bleeding in haemophilia A.

• Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children (newborn and older) with haemophilia A (congenital factor VIII deficiency), with or without factor VIII inhibitors.Population: Adults and children (newborn and older) with haemophilia ADailyMed (U.S. National Library of Medicine)

• Most common (>=10%): injection-site reactions, headache and arthralgia.International label, same product · DailyMed (U.S. National Library of Medicine)
• Postmarketing: rash, urticaria, angioedema and hypersensitivity.International label, same product · DailyMed (U.S. National Library of Medicine)

• None (US label).International label, same product · DailyMed (U.S. National Library of Medicine)

• Boxed warning: thrombotic microangiopathy and thromboembolism were reported when on average a cumulative >100 U/kg/24 hours of activated prothrombin complex concentrate (aPCC) was given for 24 hours or more during prophylaxis. Monitor if aPCC is given; discontinue aPCC and suspend Hemlibra if symptoms occur. The interaction potential may persist up to 6 months after the last dose.International label, same product · DailyMed (U.S. National Library of Medicine)
• Immunogenicity: anti-drug antibodies occurred in 5.1% of patients; rarely (<1%) neutralizing antibodies with falling concentrations may cause loss of efficacy - monitor for increased breakthrough bleeding.International label, same product · DailyMed (U.S. National Library of Medicine)
• Laboratory interference: emicizumab affects intrinsic-pathway clotting tests (aPTT, ACT, one-stage aPTT-based factor assays, clotting-based Bethesda assays); these should not be used to monitor activity, dose factor replacement or anticoagulation, or measure FVIII inhibitor titres. Chromogenic assays with bovine proteins are unaffected.International label, same product · DailyMed (U.S. National Library of Medicine)

• Activated prothrombin complex concentrate (aPCC)Clinical experience suggests an interaction causing hypercoagulability (thrombotic microangiopathy, thromboembolism) with aPCC.DailyMed (U.S. National Library of Medicine)
• Intrinsic-pathway clotting laboratory tests (aPTT-based assays)Drug-laboratory interaction: overly shortened intrinsic clotting times; use chromogenic or immuno-based assays as described in the label.DailyMed (U.S. National Library of Medicine)

• No available data on use in pregnant women; animal reproduction studies have not been conducted. Use during pregnancy only if the potential benefit for the mother outweighs the risk to the fetus. Women of childbearing potential should use contraception during treatment.International label, same product · DailyMed (U.S. National Library of Medicine)
• No information on presence in human milk or effects on the breastfed child; human IgG is known to be present in human milk. Weigh breastfeeding benefits against the mother's need for treatment.International label, same product · DailyMed (U.S. National Library of Medicine)

• Emicizumab: Bridges activated factor IX and factor X to restore the function of missing activated factor VIII needed for effective haemostasis.